Key Highlights

• TransCode Therapeutics (NASDAQ: RNAZ) adjourned its 2026 annual meeting until July 20, citing pending Nasdaq review under Rule 5110.

• All proposals received preliminary stockholder approval, but Nasdaq must complete its initial listing application review before the vote on preferred stock conversion.

• The record date for voting remains May 28, 2026, with stockholders urged to submit votes by July 19 at 11:59 p.m. ET.

• Company warns Nasdaq approval timing remains uncertain despite confidence in meeting listing criteria.

TransCode Therapeutics pushes back critical stockholder vote TransCode Therapeutics (NASDAQ: RNAZ) has postponed its 2026 annual meeting to July 20, delaying a vote regarding preferred stock conversion into common shares. The biotech firm cited an incomplete Nasdaq review as the reason for the adjournment, though preliminary votes show strong stockholder support.

Nasdaq review triggers delay

The company’s annual meeting, originally scheduled for July 2, was postponed under Nasdaq Listing Rule 5110(a). Nasdaq must approve TransCode’s initial listing application before stockholders can finalize the conversion of preferred stock. The review remains pending, and no specific timeline has been provided.

Stockholder voting remains open

Investors of record as of May 28, 2026, can still cast votes ahead of the reconvened meeting. Those who haven’t voted may do so via www.proxyvote.com or by phone until July 19 at 11:59 p.m. ET. Previously submitted votes will remain valid unless changed.

Proposals secure preliminary backing

All agenda items, including the preferred stock conversion, received the necessary stockholder support during the initial meeting. However, the administrative requirements related to Nasdaq’s review led to the postponement. The company continues to solicit votes during the adjournment period.

Uncertainty over Nasdaq approval

While TransCode expresses confidence in its adherence to Nasdaq Capital Market listing criteria, the outcome and timeline of Nasdaq’s decision remain uncertain. The company’s SEC filings highlight potential risks, including delays or rejections, that could affect stockholder plans.

Proxy statement details unchanged

There have been no changes to the proposals outlined in the definitive proxy statement filed on June 2, 2026. Stockholders are encouraged to review the document available on the SEC’s website before voting. The reconvened meeting will take place via a virtual platform.

Forward-looking statements caution

TransCode’s filings include forward-looking statements concerning Nasdaq approval and listing expectations. Actual results may differ due to regulatory, market, or operational factors outlined in the company’s latest 10-K and subsequent SEC reports.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.